Hazel Hall scholarship awarded
ASHLAND The Ashland Area American Association of University Women awarded the Hazel Hall Memorial Scholarship this year to Macy Stewart, a graduate of Boyd County High School.
Hazel Hall was a dedicated teacher at Boyd County High School and a serious lifelong learner. She lived a long, fruitful life and died this year. More than 70 years ago, as Hall began her college years, she was awarded the annual AAUW scholarship. Because she received this scholarship, she was a generous donor to the AAUW scholarship fund for many years. She wanted to pass the torch to others.
Hall graduated from what was then the Ashland Community College and went on to finish her undergraduate work at Marshall University. She served for decades as the anatomy and physiology teacher as well as a biology teacher at Boyd County High School. She leaves behind a legacy of well-educated science students.
Macy Stewart also will attend Ashland Community and Technical College and finish her undergraduate studies at Morehead State University. She plans to obtain a degree in radiologic and imaging sciences with an emphasis in computed tomography (CT) and Magnetic Resonance Imaging (MRI).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a day ago
- Medscape
AI Enhances Prostate Cancer Detection in MRI Analysis
TOPLINE: In a large-scale diagnostic study, artificial intelligence (AI) assistance led to a superior improvement in prostate cancer detection on MRI, increasing diagnostic accuracy by 3.3% compared with unassisted readings. AI support enhanced both sensitivity (96.8%) and specificity (50.1%) at detecting clinically significant prostate cancer (csPCa). METHODOLOGY: Researchers conducted a diagnostic observer study in which 61 readers (34 experts and 27 non-experts) across 17 countries assessed 360 MRI examinations of men with prostate cancer (n = 360; median age, 65 years) with and without AI assistance. The AI system used in this study was curated and developed within the international Prostate Imaging-Cancer AI (PI-CAI) Consortium for the detection and diagnosis of csPCa. The primary objective was to assess whether AI-assisted csPCa diagnosis was superior to unassisted diagnosis at the patient level using the area under the receiver operating characteristic curve (AUROC), sensitivity, and specificity at a Prostate Imaging Reporting and Data System threshold of 3 or more. TAKEAWAY: Among 360 men who were examined, 122 harboured csPCa. The AUROC was 0.916 with AI assistance vs 0.882 without, showing an improvement of 3.3% (P < .001). The sensitivity was 96.8% for AI-assisted assessments vs 94.3% for unassisted assessments, showing a significant improvement of 2.5% (P < .001). Likewise, the specificity was 50.1% for AI-assisted vs 46.7% for unassisted assessments, showing an improvement of 3.4%. Non-expert readers showed greater performance improvement with AI assistance than expert readers, achieving higher AUROC scores than those of unassisted experts. IN PRACTICE: "The findings of this diagnostic study suggest the potential of AI assistance in improving csPCa diagnosis when compared with unassisted assessments of biparametric MRI, with statistically significant improvements observed across AUROC, sensitivity, and specificity at a PI-RADS [Prostate Imaging Reporting and Data System] score of 3 or more. Notably, nonexpert readers demonstrated higher benefits from AI assistance compared with expert readers," the authors wrote. SOURCE: This study was led by Jasper J. Twilt, MSc, Minimally Invasive Image-Guided Intervention Center, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, the Netherlands. It was published online on June 13, 2025, in JAMA Network Open. LIMITATIONS: The data included were retrospectively curated within the scope of PI-CAI, resulting in a mix of consecutive and sampled cohorts. The study's generalisability requires further validation across external cohorts with varying disease prevalence, image quality, and other clinical factors. The controlled online reading workstation environment differed from readers' native settings, potentially affecting diagnostic performance. This study did not assess workflow efficiency or the clinical applicability of performance improvements in real clinical settings. DISCLOSURES: This study received funding support from Health-Holland and the European Union's Horizon 2020. Several authors reported receiving personal fees and research funding and having other ties with various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 days ago
- Medscape
First Scan for Suspected AxSpA: X-rays, MRI, or CT?
BARCELONA, Spain — Data from a prospective imaging study question the use of x-ray radiography first in the diagnostic workup of patients with suspected axial spondyloarthritis (axSpA), a practice that is currently a part of recommendations by the European Alliance of Associations for Rheumatology (EULAR). The study, which evaluated three different imaging pathways based on whether x-ray radiography, MRI, or CT of the sacroiliac joint (SIJ) was used first, found that the two latter approaches yielded a higher diagnostic efficacy than the radiograph-first approach. While just 13% of 30 people who were in the radiograph-first arm of the study were confirmed as having axSpA after the initial scan, 22% of 91 patients in the MRI-first and 30% of 84 people in the CT-first arms were given an axSpA diagnosis. X-ray, MRI, or CT first? Dominik Deppe, MD 'To x-ray or not to x-ray? What may sound somewhat philosophical, is a relevant question,' said study investigator Dominik Deppe, MD, who presented the findings at European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting. Deppe, a doctoral student in the Department of Radiology at Charité – Universitätsmedizin Berlin, Berlin, Germany, explained that although radiographs could show certain structural lesions, such as erosions, sclerosis, or ankylosis, and used relatively low levels of radiation, interpretation could be problematic. 'Even among experts, inter-reader reliability remains low,' Deppe said. MRIs are often performed if the results on radiography are negative or inconclusive. Such scans provide additional insights, he added, and can show both structural and inflammatory lesions, such as bone marrow edema. However, the high cost and low availability of MRI relative to radiography, however, were issues, he acknowledged. This is where CT could perhaps prove most useful. Although it's not part of the standard imaging pathway as yet, it is 'a gold standard for structural lesions,' Deppe said. He added: 'Historically, CT is considered to have high radiation exposure, but nowadays, we can perform CT with ultra-low dose techniques that allow us to reduce radiation exposure to a level that is comparable, or even less, compared to conventional x-rays.' Strategies Compared and Results The study included 205 people with suspected axSpA, who were randomly allocated into one of three arms: 30 to a radiograph-first or 'standard' arm, 91 to an MRI-first arm, and 84 to a CT-first arm. Scans were designated positive or negative by the consensus of two specialized musculoskeletal radiologists who were blinded to the clinical data. A positive result was defined as clear signs of structural or inflammation suggestive of axSpA and no further imaging was done. Those with negative scans underwent a subsequent scan with another method; those in the radiograph-first arm had an MRI scan and then a CT scan, those in the MRI-first arm had a CT scan, and those in the CT-first arm had an MRI scan. The results are preliminary because the study is ongoing and results from the final diagnosis by a rheumatologist are not yet available, Deppe said. He reported that in the radiograph-first arm, 26 (87%) people had a negative scan and then had an MRI scan. This was positive in three (11%) and negative in 23 (88%) of people. None of the people with a negative MRI scan had a positive CT scan. In the MRI-first arm, scans were positive in 20 (22%) and negative in 71 (78%) of people. Again, CT added no further cases among the people who were also MRI-negative. Finally, in the CT-first arm, there were 25 (30%) positive and 59 (70%) negative scans. MRI performed in the CT-negative patients detected two (3%) additional cases of confirmed axSpA. Deppe said: 'Our standard approach, [which] we're using right now, has the lowest diagnostic efficacy, compared to the MRI-first and CT-first approach.' Patient Characteristics Information about patient demographics were not presented, however, which prompted Uta Kiltz, MD, a senior rheumatologist at Rheumazentrum Ruhrgebiet, Herne, Germany, to ask for clarification and about the study design. 'Can you give some information about the population you included in the study?' she asked. 'I think we need to have some more context about the decision-making process to really understand the results.' Deppe responded that the patients had been referred with the suspicion and not confirmed diagnosis of axSpA and had been randomized through a third party into the three different imaging arms. Topline patient demographics had been given in the abstract, which stated that the mean age of the population studied was 38 years (SD, 10.58 years) and just over half (58%) were women. Around half (53%) of the study population was HLA-B27 positive. The mean C-reactive protein level was 3.66 mg/L, and the mean BMI was 25.57. The mean duration of back pain was around 8 years, and 70.6% of people had signs of inflammatory back pain. Questions Raised Several discussants raised concerns about the study design and the interpretation of these early findings. Eric Ruderman, MD, of Northwestern University Feinberg School of Medicine, Chicago, questioned why all patients did not receive all three imaging modalities: 'Ultimately, you don't know the diagnostic specificity of the [ultra] low-dose CT. Why didn't you do all three images in each patient, so that you can actually make a comparison once you have the confirmed diagnosis?' Deppe replied that the team wanted to be pragmatic: 'We wanted to evaluate the clinical settings where the patient does not undergo every imaging, but if we found positive results, as in the clinical practice, we don't need further imaging, and this is something we want to demonstrate in the study.' Xenofon Baraliakos, MD, head of rheumatology at the Rheumazentrum Ruhrgebiet, and the new president of EULAR, raised concerns about potential false positives: 'What happens if the x-ray is it was falsely positive? Have you been able to check for that?' Deppe acknowledged the limitation: 'I think this is something we have to do when we have the final diagnosis by the rheumatologist, to see whether we missed or misinterpreted some of the images.' This study was independently supported. Deppe had no conflicts of interest. The commentators were not involved in the study.
Yahoo
2 days ago
- Yahoo
Bayer Files for Approval of gadoquatrane in the U.S.
FDA submission seeks approval for investigational gadolinium-based contrast agent (GBCA) gadoquatrane for contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and other body regions for adults and pediatric patients including term neonates Submitted dose corresponds to a 60 percent reduction in gadolinium compared to macrocyclic GBCAs dosed at 0.1 mmol gadolinium per kilogram of body weight Not intended for media outside of the US WHIPPANY, N.J., June 17, 2025--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S., corresponding to a 60 percent reduction compared to macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. The submission of gadoquatrane to the US FDA is based on positive data from the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane in adult and pediatric patients globally. The first results from the Phase III QUANTI CNS study were presented at the European Congress of Radiology (ECR) in February of this year and further results are planned to be presented at upcoming scientific meetings. Nearly 40 million MRI scans are performed each year in the United States. "There is a rising need for medical imaging, among others driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases," said Dr. Konstanze Diefenbach, Head of Radiology Research & Development, Bayer. "As a leader in radiology, we are committed to advancing innovation in this field, including options to reduce the gadolinium dose. Patients can benefit from a dose reduction, especially patients with chronic conditions who require multiple contrast-enhanced MRI examinations during their lifetime. This is in line with guidance from health authorities and guidelines from scientific bodies which recommend using the lowest dose required to obtain the needed clinical information." Bayer recently announced the submission of gadoquatrane to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, marking the first application for marketing authorization for the investigational contrast agent. Further regulatory applications to health authorities worldwide are planned for the coming months. About the Phase III development program QUANTIThe pivotal QUANTI clinical development program investigated gadoquatrane at a dose of 0.04 mmol Gd/kg body weight, which represents a 60 percent lower gadolinium dose compared to macrocyclic contrast agents dosed at 0.1 mmol Gd/kg body weight. QUANTI consisted of two large multinational, randomized, prospective double-blind, crossover Phase III studies – QUANTI CNS (Central Nervous System) and QUANTI OBR (Other Body Regions) – as well as the QUANTI Pediatric study. In total, 808 patients in 15 countries participated in the program. The QUANTI study results show that gadoquatrane met the primary and secondary efficacy endpoints of the studies assessing visualization parameters and lesion detection. Results of QUANTI Pediatric demonstrated that the pharmacokinetic behavior of gadoquatrane in children is similar to that in adults. The observed safety profile in adults as well as pediatric patients from birth to < 18 years of age in the QUANTI studies was generally consistent with previous data on gadoquatrane and other macrocyclic GBCAs. No new safety signals were observed. About gadoquatraneGadoquatrane is Bayer's investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. This low dose gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity. About MRIWith an estimated 65 million procedures performed annually worldwide, contrast-enhanced MRI plays a key role in the healthcare continuum. MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection and monitoring of diseases. About Radiology at BayerBuilding on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer's comprehensive offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. In 2024, Bayer's radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including the integration of AI. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Contact for media inquiries: Victoria Vigener, phone +49 151 23438911 Email: Contact for US media inquiries: Jennifer May, phone, 412-656-8192 Email: Find more information at Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
